Of note, a patient with AML associated with a DEK-NUP214 fusion displayed a remarkable response to treatment with Selinexor in a phase I clinical trial [42], underscoring the clinical relevance of the Crm1/NUP214 interaction. Here, XPO1 is linked to acute myeloid leukemia.